266 related articles for article (PubMed ID: 31122520)
1. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y
Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520
[TBL] [Abstract][Full Text] [Related]
2. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
3. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
Song SQ; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
[TBL] [Abstract][Full Text] [Related]
4. Relapsed or refractory gestational trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen.
Mao Y; Wan X; Lv W; Xie X
Int J Gynaecol Obstet; 2007 Jul; 98(1):44-7. PubMed ID: 17481633
[TBL] [Abstract][Full Text] [Related]
5. Refractory Gestational Trophoblastic Neoplasia: A Novel Drug Combination With Paclitaxel and Carboplatin Produces Durable Complete Remission.
Rathod PS; Kundargi R; Pallavi VR; Vijay CR; Devi UK; Bafna UD
Int J Gynecol Cancer; 2015 Nov; 25(9):1737-41. PubMed ID: 26401644
[TBL] [Abstract][Full Text] [Related]
6. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
7. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis.
Alifrangis C; Agarwal R; Short D; Fisher RA; Sebire NJ; Harvey R; Savage PM; Seckl MJ
J Clin Oncol; 2013 Jan; 31(2):280-6. PubMed ID: 23233709
[TBL] [Abstract][Full Text] [Related]
8. Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide.
Kanno T; Matsui H; Akizawa Y; Usui H; Shozu M
J Gynecol Oncol; 2018 Nov; 29(6):e89. PubMed ID: 30207097
[TBL] [Abstract][Full Text] [Related]
9. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
[TBL] [Abstract][Full Text] [Related]
10. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia.
Lybol C; Thomas CM; Blanken EA; Sweep FC; Verheijen RH; Westermann AM; Boere IA; Reyners AK; Massuger LF; van Hoesel RQ; Ottevanger PB
Eur J Cancer; 2013 Mar; 49(4):860-7. PubMed ID: 23099004
[TBL] [Abstract][Full Text] [Related]
11. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
Zhou Y; Feng FZ; Xiang Y; Wan XR
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
[TBL] [Abstract][Full Text] [Related]
12. [Curative effects and influenced factors of EMA-CO as an initial regimen for the treatment of high-risk gestational trophoblastic neoplasia].
Liu W; Zhao W; Zhang YQ; Huang XF
Zhonghua Yi Xue Za Zhi; 2018 Dec; 98(47):3896-3899. PubMed ID: 30585038
[No Abstract] [Full Text] [Related]
13. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
[TBL] [Abstract][Full Text] [Related]
14. High-risk metastatic gestational trophoblastic neoplasia. Primary management with EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Cagayan MS
J Reprod Med; 2012; 57(5-6):231-6. PubMed ID: 22696818
[TBL] [Abstract][Full Text] [Related]
15. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
16. Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia.
Maestá I; Horowitz NS; Goldstein DP; Bernstein MR; Ramírez LA; Moulder J; Berkowitz RS
Int J Gynecol Cancer; 2015 May; 25(4):734-40. PubMed ID: 25675037
[TBL] [Abstract][Full Text] [Related]
17. EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients.
Lu WG; Ye F; Shen YM; Fu YF; Chen HZ; Wan XY; Xie X
Int J Gynecol Cancer; 2008; 18(2):357-62. PubMed ID: 17711444
[TBL] [Abstract][Full Text] [Related]
18. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
19. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
20. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
